- Home
- Publications
- Publication Search
- Publication Details
Title
A small molecule inhibitor of VSIG-8 prevents its binding to VISTA
Authors
Keywords
-
Journal
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-04-11
DOI
10.1007/s10637-022-01244-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An active small molecule modulator M351‐0056 targeting the novel immune‐checkpoint protein VISTA
- (2021) Xinlei Hu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Structural Basis of VSIG3: The Ligand for VISTA
- (2021) Xiaoxue Xie et al. Frontiers in Immunology
- PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
- (2021) Pottayil G. Sasikumar et al. Communications Biology
- Structural insight into T cell coinhibition by PD-1H (VISTA)
- (2020) Benjamin T. Slater et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation
- (2019) Nishant Mehta et al. Cell Reports
- 1209PExcellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1
- (2019) V Radhakrishnan et al. ANNALS OF ONCOLOGY
- VISTA is an acidic pH-selective ligand for PSGL-1
- (2019) Robert J. Johnston et al. NATURE
- The Cancer Immunotherapy Revolution
- (2018) Priscilla N. Kelly SCIENCE
- VSIG-3 as a ligand of VISTA inhibits human T cell function
- (2018) Jinghua Wang et al. IMMUNOLOGY
- Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules
- (2018) Jeffrey Yang et al. MEDICINAL RESEARCH REVIEWS
- Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma
- (2017) Chunyan Hao et al. MEDICINE
- Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
- (2017) Hojabr Kakavand et al. MODERN PATHOLOGY
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
- (2017) Christine Böger et al. OncoImmunology
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- VISTA Is an Immune Checkpoint Molecule for Human T Cells
- (2014) J. L. Lines et al. CANCER RESEARCH
- Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
- (2013) C. Zielinski et al. ANNALS OF ONCOLOGY
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
- (2011) D. B. Flies et al. JOURNAL OF IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started